StageZero Life Sciences to Present at ii6 Summit in Toronto

Biotech & MedTech

August 7, 2019 (Source) – StageZero Life Sciences Ltd (TSX:SZLS) (“StageZero” or the “Company”) today announced that Chairman & CEO, James Howard-Tripp will be presenting at the ii6 Summit, Thursday, August 8 at the Omni King Edward Hotel in Toronto. The event, which is sponsored by InvestorIntel, gives CEOs an opportunity to present their companies to multiple self-directed, accredited investors.

“We look forward to presenting the StageZero offering to this sophisticated group of investors and to explain our approach to early cancer detection through blood,” said Howard-Tripp. “We are particularly excited to build greater awareness around our next generation test Aristotle™, a test for the simultaneous detection of ten discrete cancers from a single sample of blood.”

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection (Stage 0) of cancer and multiple disease states through whole blood. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of Aristotle is currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as “expects”, “will” and similar expressions, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company’s actual events to differ materially from those projected herein. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.